Advertisement Micrus receives CE Mark authorization for Pharos Vitesse stent - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Micrus receives CE Mark authorization for Pharos Vitesse stent

Micrus Endovascular has announced that its Pharos Vitesse intracranial stent has received CE Mark authorization for commercial distribution in the European Union and all countries recognizing the CE Mark.

The Pharos Vitesse is Micrus Endovascular’s balloon-expandable stent for intracranial ischemic stenosis and wide-neck aneurysm treatment.

Micrus intends to immediately begin selling the Pharos Vitesse stent in the approved geographies through its direct sales and distribution network.

The Pharos Vitesse is manufactured exclusively for Micrus Endovascular through a collaborative agreement with Switzerland-based Biotronik.

John Kilcoyne, chairman and CEO of Micrus Endovascular, said: “CE Mark authorization of the Pharos Vitesse stent supports our expansion into the large ischemic stroke market with a product that has important value-added features.”